

# UnitedHealthcare Commercial Medical Policy Update Bulletin: January 2024

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

## **Take Note**

#### **Annual CPT/HCPCS Code Updates**

Beginning **Jan. 1, 2024**, all applicable Medical Policies and Medical Benefit Drug Policies will be updated to reflect the 2024 Current Procedural Terminology (CPT°) and Healthcare Common Procedure Coding System (HCPCS) code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- American Medical Association: Current Procedural Terminology: CPT<sup>®</sup>
- Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System (HCPCS) Quarterly Update

For the list of impacted policies and corresponding details, click here.

# **Medical Policy Updates**

| Policy Title   | Status  | Effective Date |
|--|---------|----------------|
| Airway Clearance Devices   | Revised | Mar. 1, 2024   |
| Apheresis  | Revised | Mar. 1, 2024   |
| Deep Brain and Cortical Stimulation  | Revised | Feb. 1, 2024   |
| Elective Inpatient Services  | Revised | Feb. 1, 2024   |
| Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation       | Updated | Feb. 1, 2024   |
| Genetic Testing for Hereditary Cancer  | Revised | Feb. 1, 2024   |
| Hearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable | Updated | Feb. 1, 2024   |
| Implanted Electrical Stimulator for Spinal Cord                                  | Updated | Feb. 1, 2024   |
| Intensity-Modulated Radiation Therapy  | Revised | Feb. 1, 2024   |
| Interspinous Fusion and Decompression Devices                                    | Revised | Feb. 1, 2024   |
| Liposuction for Lipedema   | Revised | Feb. 1, 2024   |
| Obstructive and Central Sleep Apnea Treatment                                    | Revised | Mar. 1, 2024   |
| Outpatient Surgical Procedures - Site of Service                                 | Updated | Jan. 1, 2024   |
| Percutaneous Patent Foramen Ovale (PFO) Closure                                  | Revised | Feb. 1, 2024   |
| Preventive Care Services   | Revised | Feb. 1, 2024   |
| Proton Beam Radiation Therapy  | Revised | Feb. 1, 2024   |
| Radiation Therapy: Fractionation, Image-Guidance, and Special Services           | Revised | Feb. 1, 2024   |
| Sacral Nerve Stimulation for Urinary and Fecal Indications                       | Revised | Feb. 1, 2024   |
| Skin and Soft Tissue Substitutes   | Revised | Feb. 1, 2024   |
| Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery                | Revised | Feb. 1, 2024   |
| Total Artificial Disc Replacement for the Spine                                  | Revised | Feb. 1, 2024   |

| Policy Title                                   | Status  | Effective Date |
|--|---------|----------------|
| Transcranial Magnetic Stimulation              | Updated | Feb. 1, 2024   |
| Treatment of Temporomandibular Joint Disorders | Revised | Mar. 1, 2024   |

# Medical Benefit Drug Policy Updates

| Policy Title   | Status  | Effective Date |
|--|---------|----------------|
| Actemra® (Tocilizumab) Injection for Intravenous Infusion  | Revised | Feb. 1, 2024   |
| Cimzia® (Certolizumab Pegol)   | Revised | Feb. 1, 2024   |
| Clotting Factors, Coagulant Blood Products & Other Hemostatics   | Revised | Feb. 1, 2024   |
| Eloctate® [Antihemophilic Factor (Recombinant), FC Fusion Protein] for Connecticut Lines of Business (for Oxford Only) | Updated | Feb. 1, 2024   |
| Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)   | Updated | Feb. 1, 2024   |
| Ketalar® (Ketamine) and Spravato® (Esketamine)   | Revised | Feb. 1, 2024   |
| Neonatal Fc Receptor Blockers (Vyvgart®, Vyvgart® Hytrulo, & Rystiggo®)  | Revised | Jan. 1, 2024   |
| Ophthalmologic Complement Inhibitors   | Updated | Jan. 1, 2024   |
| Provider Administered Drugs – Site of Care   | Revised | Jan. 1, 2024   |
| Reblozyl® (Luspatercept-Aamt)  | Revised | Feb. 1, 2024   |
| Roctavian <sup>™</sup> (Valoctocogene Roxaparvovec-Rvox)   | Updated | Jan. 1, 2024   |
| Testosterone Replacement or Supplementation Therapy  | Revised | Feb. 1, 2024   |

### **General Information**

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

**Note**: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Medical Policy and Medical Benefit Drug Policy updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

#### **Policy Update Classifications**

#### New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

#### Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

#### Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

#### Replaced

An existing policy has been replaced with a new or different policy

#### Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Medical Policies and Medical Benefit Drug Policies is available at **UHCprovider.com** > Policies and Protocols > Commercial Policies > Medical & Drug Policies.